⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 19, 2024eJHaemOpen Access

Outcomes of melphalan 140 mg/m² followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience

Dario Melotti Samir Asher Ethan Troy‐Barnes George Nesr William Wilson Marquita Camilleri Rakesh Popat Ke Xu Neil Rabin Jonathan Sive Xenofon Papanikolaou Lydia Lee Annabel McMillan Kwee Yong Chara Kyriakou

View Full Paper

Ask AI

Bookmark

Share

Abstract

High-dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant-eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Melotti et al. (2024) studied this question.

synapsesocial.com/papers/68e5bc29b6db643587553d4e https://doi.org/10.1002/jha2.977

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective studyRetrospective Study · 2026
2Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.2024
3Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.2025
4Second autologous hematopoietic stem cell transplantation in multiple myelomaRetrospective Study · 2026
5Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapyPrognostic Study · 2000 · 77 citations

More related papers

Real world outcomes of high dose melphalan conditioning prior to autologous stem cell transplant in extramedullary multiple myeloma vs. multiple myeloma without extramedullary involvement: A single center experience.2024
High-dose melphalan and autologous stem cell transplantation in multiple myeloma: efficacy and minimal residual disease’s impact on progression-free survival2026
Retrospective Analysis of Patients with Multiple Myeloma Post Autologous Stem Cell Transplant2025

More from eJHaem

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta‐Analysis of Clinical TrialsThu,
Ovarian Reserve in Women of Reproductive Age With Sickle Cell Anaemia: A Scoping ReviewThu,